Memphis Pharmaceuticals & Chemical Industries (MPCI) Stock Overview
Engages in the research, development, manufacture, marketing, and distribution of pharmaceutical products for human and veterinary use in Egypt and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
MPCI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Memphis Pharmaceuticals & Chemical Industries Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م223.92 |
| 52 Week High | ج.م238.78 |
| 52 Week Low | ج.م67.02 |
| Beta | 0.12 |
| 1 Month Change | 6.88% |
| 3 Month Change | 41.96% |
| 1 Year Change | 224.47% |
| 3 Year Change | 639.25% |
| 5 Year Change | 795.68% |
| Change since IPO | 640.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| MPCI | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | 1.3% | 0.2% | 1.3% |
| 1Y | 224.5% | 123.1% | 59.6% |
Return vs Industry: MPCI exceeded the EG Pharmaceuticals industry which returned 121.8% over the past year.
Return vs Market: MPCI exceeded the EG Market which returned 58.6% over the past year.
Price Volatility
| MPCI volatility | |
|---|---|
| MPCI Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in EG Market | 8.4% |
| 10% least volatile stocks in EG Market | 3.4% |
Stable Share Price: MPCI has not had significant price volatility in the past 3 months compared to the EG market.
Volatility Over Time: MPCI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1940 | n/a | Mohamed Ibrahim | www.memphis.com.eg |
Memphis Pharmaceuticals & Chemical Industries engages in the research, development, manufacture, marketing, and distribution of pharmaceutical products for human and veterinary use in Egypt and internationally. The company offers human health products in various therapeutic areas, including anti-infective, central nervous system, dermatological, cardiovascular diseases, vitamins and minerals, analgesics and antipyretics, respiratory system, and gastrointestinal and metabolic disorders. It also provides products for anthelmintic, anti-hypertensive angiotensin blockers, anti-dandruff, antifungal, antihistamine, anti-pyretic, anti-spasmodic, antigout, anti-tuberculosis, anxiolytics and antipsychotic, antitussive, calcium deficiency treatment, cold and flu, emergency injection, folic acid deficiency treatment, gastric-enteritis pre-surgical, heart burn, immunity enhancer, injectable and oral corticosteroids, laxative, local anesthetic, local treatment vitiligo, loop diuretic, muscle relaxant, narcotic opioid, NSAID, oral and topical antibiotics, antiemetic, peptic ulcer proton pump inhibitor, prolactin inhibitor, local treatment psoriasis, topical anti-inflammatory, topical moisturizing, migraine, and urinary incontinence antispasmodics, as well as vitamin b, c, d, and k deficiency treatment.
Memphis Pharmaceuticals & Chemical Industries Fundamentals Summary
| MPCI fundamental statistics | |
|---|---|
| Market cap | ج.م5.09b |
| Earnings (TTM) | ج.م518.98m |
| Revenue (TTM) | ج.م1.68b |
Is MPCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MPCI income statement (TTM) | |
|---|---|
| Revenue | ج.م1.68b |
| Cost of Revenue | ج.م990.33m |
| Gross Profit | ج.م685.08m |
| Other Expenses | ج.م166.10m |
| Earnings | ج.م518.98m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 22.81 |
| Gross Margin | 40.89% |
| Net Profit Margin | 30.98% |
| Debt/Equity Ratio | 11.8% |
How did MPCI perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/17 23:32 |
| End of Day Share Price | 2026/06/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Memphis Pharmaceuticals & Chemical Industries is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.